Skip to search formSkip to main contentSkip to account menu

MM-151

Known as: Anti-EGFR Monoclonal Antibody Mixture MM-151 
An oligoclonal therapeutic composed of three fully human monoclonal antibodies targeting epidermal growth factor receptor (EGFR or ErbB1), with… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 122: Preclinical update on targetingKRASwild-type colorectal cancer with an EGFR-targeted monoclonal tri-body mixture, MM-151
2016
2016
Abstract B33: The oligoclonal antibody MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations
The anti-EGFR antibodies cetuximab and panitumumab are used to treat ‘RAS’ wild type colorectal cancers (CRCs), but their… 
2016
2016
Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors.
2518Background: MM-151 is a mixture of three IgG1 antibodies designed to bind simultaneously to non-overlapping EGFR epitopes and… 
2016
2016
A phase 1b/2 study combining MM-151 + nal-IRI + 5-FU + leucovorin in RAS-wildtype metastatic colorectal cancer (mCRC).
TPS3633Background: Colorectal cancer is a leading cause of cancer death worldwide and the third most common cancer in men and… 
2016
2016
A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers.
TPS11619Background: The Epidermal Growth Factor Receptor (EGFR) is a key driver of tumor growth in colorectal cancer (CRC… 
2016
2016
Abstract 1199: A network biology screen reveals ligand-receptor pathway connections and resistance mechanisms to RTK-directed therapies in cancer cells
Purpose: Although there are many well-defined signaling pathways in tumor cells that provide druggable targets, emergence of… 
2015
2015
Safety, pharmacology, and preliminary clinical activity of MM-151: An oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors.
647 Background: MM-151 is an oligoclonal anti-EGFR antibody combination designed to provide enhanced targeting of the EGFR… 
Review
2015
Review
2015
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer
Introduction: Although epidermal growth factor receptor (EGFR) inhibitors have progressively become a relevant therapeutic arm in… 
2014
2014
Phase 1 trial of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors.
2518 Background: MM-151 is a novel oligoclonal anti-EGFR antibody combination designed to overcome key challenges of the EGFR… 
2014
2014
329 A first-in-human study evaluating the safety and pharmacology of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)